Explore the Program by Day

Thursday, November 3, 2022
Sessions Time Speaker
Registration Open1:30 PM- 7:00 PM
KCA Think Tank Meeting (by Invitation Only)2:00 PM- 5:00 PM
Welcome and First Time Attendee Happy Hour (In-person Only)
Marker 10, Hyatt Regency Austin Lobby bar
5:00 PM- 6:00 PM
A First-line Treatment Option for Your Adult Patients With Advanced Renal Cell Carcinoma
Supported by Eisai
Hill Country Ballroom
6:00 PM- 7:00 PMSandy Liu, MD
City of Hope Orange County
RCC Clinical Consults: Making Difficult Treatment Decisions at the Intersection of the Data and the Real World
(CME Session Provided by PeerView Oncology)
Supported by AVEO, BMS, Eisai, Exelixis, and Merck
Hill Country Ballroom
7:00 PM- 8:00 PM Sumanta “Monty” K. Pal, MD, FASCO
City of Hope
Friday, November 4, 2022
SessionsTimeSpeaker
Registration Open6:30 AM- 6:00 PM
Poster and Exhibit Hall Open6:30 AM6:30 PM
Women in RCC Networking (In-person with Virtual Zoom Option)
Big Bend Ballroom A/B
6:45 AM- 7:45 AMMaria Carlo, MD
Memorial Sloan Kettering Cancer Center
Break7:45 AM- 8:00 AM
Welcome to 2022 IKCS: North America
Zilker 3-4
8:00 AM- 8:10 AMEric A. Singer, MD, MA, MS, FACS, FASCO
Ohio State Wexner Medical Center

Tian Zhang, MD, MHS
University of Texas Southwestern Medical Center
Welcome and Session 1: Treatment Debates
Zilker 3-4
8:10 AM- 10:00 AMVitaly Margulis, MD
University of Texas Southwestern Medical Center

Rana McKay, MD
University of California, San Diego
Debate 1: Surveillance vs Intervention8:10 AM- 8:45 AMPhillip M. Pierorazio, MD
Penn Presbyterian Medical Center, Penn Medicine

Raquib Hannan, MD, PhD
University of Texas Southwestern Medical Center
Debate 2: Adjuvant or Not?8:45 AM- 9:20 AMBradley McGregor, MD
Dana-Farber Cancer Institute

Naomi Haas, MD
Penn Medicine
Debate 3: Doublet or Triplet as first-line Treatment in Kidney Cancer9:20 AM- 10:00 AMYousef Zakharia, MD
University of Iowa

Rana McKay, MD
University of California, San Diego
Session 2: Side-effect Management and Quality of Life Perspectives in Kidney Cancer Treatment
Zilker 3-4
10:00 AM- 11:00 AMKiran Virdee, RN CCRN-K
Memorial Sloan Kettering Cancer Center
Disease and Symptom Management, Supportive Care Options, and Understanding Patient-reported Outcomes10:00 AM- 10:20 AMElizabeth Wulff-Burchfield, MD
University of Kansas Medical Center
The Patient Perspective on Side-effects and Care10:20 AM- 10:25 AMLaura Esfeller
Daily Aspects of Side-effect Management Logistics10:25 AM- 10:35 AMKiran Virdee, RN CCRN-K
Memorial Sloan Kettering Cancer Center
Multidisciplinary Panel Discussion and Q+A: Navigating Renal Cell Carcinoma Side-effects Beyond Urology and Oncology10:35 AM- 11:00 AMKiran Virdee, RN CCRN-K
Memorial Sloan Kettering Cancer Center

Elizabeth Wulff-Burchfield, MD
University of Kansas Medical Center

Yan Liu, MD, PhD
Ascension Texas Cardiovascular

Afreen Shariff, MD, MBBS
Duke Health

Michael Dougan, MD, PhD
Massachusetts General Hospital
Break11:00 AM- 11:30 AM
Session 3: The Professional State of RCC
Zilker 3-4
11:30 AM- 11:50 AMW. Kimryn Rathmell, MD, PhD
Vanderbilt University Medical Center
The Professional State of RCC11:30 AM- 11:50 AM
Session 4: Professional Development Workshop (In-person Only)11:50 AM- 1:00 PMEric A. Singer, MD, MA, MS, FACS, FASCO
Ohio State Wexner Medical Center

Tian Zhang, MD, MHS
University of Texas Southwestern Medical Center
Introduction11:50 AM- 11:55 AMEric A. Singer, MD, MA, MS, FACS, FASCO
Ohio State Wexner Medical Center

Tian Zhang, MD, MHS
University of Texas Southwestern Medical Center
Breakout Group 1: Professional Development and What I Wish I’d Known 10 Years Earlier11:55 AM- 12:30 PMBradley C. Leibovich, MD
Mayo Clinic

Tian Zhang, MD, MHS
University of Texas Southwestern Medical Center

Daniel J. George, MD
Duke University
Breakout Group 2: Learning from Others’ Experience- How and When to Consider Career Moves11:55 AM- 12:30 PMBrian Rini, MD
Vanderbilt University Medical Center

Eric A. Singer, MD, MA, MS, FACS, FASCO
Ohio State Wexner Medical Center

Jodi Maranchie, MD
University of Pittsburgh Medical Center

W. Kimryn Rathmell, MD, PhD
Vanderbilt University Medical Center
Breakout Group 3: Career Opportunities in Industry and Options Outside of Academia11:55 AM- 12:30 PMSubramanian Hariharan, MD, FACP
Pfizer

Jose R. Perez, MD
Exelixis

Bradley McGregor, MD
Dana-Farber Cancer Institute
Bringing it Back Together: Insights from Breakout Group Discussions and Wrap-Up12:30 PM- 1:00 PM
Lunch and Poster Session
Zilker North Lobby and Zilker 1-2
1:00 PM- 2:30 PMView Poster Listing
Break1:00 PM- 1:15 PM
A Combination Treatment for Patients with Advanced Renal Cell Carcinoma
Supported by Exelixis
Hill Country Ballroom
1:15 PM- 2:15 PMJohn Sarantopoulos, MD
UT Health San Antonio
Break2:15 PM- 2:30 PM
Session 5: Keynote Lecture
Zilker 3-4
2:30 PM- 3:15 PMTian Zhang, MD, MHS
University of Texas Southwestern Medical Center
Introduction2:30 PM- 2:35 PMTian Zhang, MD, MHS
University of Texas Southwestern Medical Center
Keynote Lecture2:35 PM- 3:00 PMDavid F. McDermott, MD
Beth Israel Deaconess
Question and Answer3:00 PM- 3:15 PM
Session 6: Multidisciplinary Team Approaches to Rare Subtypes
Zilker 3-4
3:15 PM- 4:30 PMJodi Maranchie, MD
University of Pittsburgh Medical Center
Collecting Duct, Sarcomatoid, and Rhabdoid Subtypes3:15 PM- 3:27 PMDavid Braun, MD, PhD
Yale School of Medicine
Translocation Type Subtypes3:27 PM- 3:37 PMSrinivas R. Viswanathan, MD, PhD
Dana-Farber Cancer Institute
Renal Medullary Cancer3:37 PM- 3:47 PMPavlos Msaouel, MD, PhD
University of Texas MD Anderson Cancer Center
Abstract 1: Spatial molecular imaging to profile the epithelial to
mesenchymal transition and immune crosstalk in sarcomatoid
renal cell carcinoma.
3:47 PM- 3:55 PMAllison May, MD
University of Michigan
Abstract 2: Biomarkers of Disease Burden and Treatment Response in Renal Medullary Carcinoma
*3rd Place Abstract Merit Award
3:55 PM- 4:02 PMKyle A. Blum, MD, MS
University of Texas Houston, MD Anderson Cancer Center
Best Practices for Multidisciplinary Care Teams Discussion and Panel Question and Answer4:03 PM- 4:30 PMPayal Kapur, MD
University of Texas Southwestern

Ivan Pedrosa, MD, PhD
University of Texas Southwestern

Steven Chang, MD, MS
Dana-Farber/ Brigham and Women’s Cancer Center

Stephanie Berg, DO
Loyola University

Chad Tang, MD
University of Texas MD Anderson Cancer Center
Session 7: Academy of Kidney Cancer Investigators
Zilker 3-4
4:30 PM- 5:15 PMBrian Rini, MD
Vanderbilt University Medical Center
Introduction4:30 PM- 4:40 PMBrian Rini, MD
Vanderbilt University Medical Center
Circulating Biomarkers in Renal Cell Carcinoma4:40 PM- 4:55 PMWenxin Xu, MD
Dana-Farber Cancer Institute
Recurrent Genomic Alterations Driving Clear Cell Renal Cell Carcinoma Development4:55 PM- 5:10 PMPeter Ly, PhD
University of Texas Southwestern
Panel Discussion and Question and Answer5:10 PM- 5:15 PM
Remembering Nicholas J. Vogelzang5:15 PM- 5:30 PM
Networking Session: Evening Reception and Poster Session
Zilker North Lobby and Zilker 1-2
5:30 PM- 6:45 PMView Poster Listing
Networking Session: Poster Walks (In-person)
Poster Hall, Zilker North Lobby
5:45 PM- 6:30 PMShawn Dason, MD
Ohio State University Medical Center

Sumanta “Monty” K. Pal, MD, FASCO
City of Hope
Networking Session: Poster Walks (Virtual)
Online via Zoom
5:45 PM- 6:30 PMBradley McGregor, MD
Dana-Farber Cancer Institute

Phillip Pierorazio, MD
Penn Presbyterian Medical Center, Penn Medicine
A Treatment Option for Certain Patients With RCC in the Adjuvant Setting
Supported by Merck
Hill Country Ballroom
6:00 PM- 7:00 PMAmit Mehta, MD
Premier Hematology Oncology
Saturday, November 5, 2022
SessionsTimeSpeaker
Early Morning Run (In-person only, Advance Registration Required)
Hyatt Regency Hotel Lobby
6:30 AM- 7:30 AMBradley McGregor, MD
Dana-Farber Cancer Institute
Early Morning Yoga (In-person only, Advance Registration Required)
Big Bend Ballroom A/B
6:30 AM- 7:30 AMPhillip Pierorazio, MD
Penn Presbyterian Medical Center, Penn Medicine
Registration Open6:30 AM- 2:00 PM
Poster and Exhibit Hall Open6:30 AM- 2:00 PMView Poster Listing
Day 2 Welcome and Updates from the Kidney Cancer Association
Zilker 3-4
8:00 AM- 8:15 AM
Kidney Cancer Association Initiatives, Progress, and New Horizons8:00 AM- 8:15 AMDaniel J. George, MD
Duke University
Session 8: Regulatory for New Trials
Zilker 3-4
8:15 AM- 9:15 AMSumanta “Monty” K. Pal, MD, FASCO
City of Hope
FDA 101: Illuminating the Black Box8:17 AM- 8:30 AMElaine Chang, MD
US Food and Drug Administration
Choosing Endpoints and Designs of Future Trials: OS vs PFS and Comparator Cohorts8:30 AM- 8:43 AMChung-Han “Joe” Lee, MD, PhD, BS
Memorial Sloan Kettering Cancer Center
Experiences With Patient Acceptance of Clinical Trials8:43 AM- 8:56 AMLaura S. Wood, RN, MSN, OCN, Ret.
Cleveland Clinic Taussig Cancer Center
Abstract 3: Critical assessment of eligibility criteria in contemporary renal cell carcinoma (RCC) trials evaluating systemic therapy8:56 AM- 9:03 AMDaniela V. Castro, MS
City of Hope Comprehensive Cancer Center
Panel Discussion and Question and Answer9:04 AM- 9:15 AM
Session 9: Oral Abstract Session
Zilker 3-4
9:15 AM- 10:00 AMYousef Zakharia, MD
University of Iowa
Abstract 5: CD200-mediated immune evasion in clear cell renal cell carcinoma
*1st Place Abstract Merit Award
9:16 AM- 9:23 AMGemma E. Davies, BSc, MSc
Cardiff University
Abstract 6: Clinical outcomes with nivolumab/ipilimumab (nivo/ipi) with or without CBM588 in metastatic renal cell carcinoma (mRCC): Long-term follow-up of a randomized phase Ib clinical trial
*2nd Place Abstract Merit Award
9:24 AM- 9:31 AMNazli Dizman, MD
Yale New Haven Hospital
Abstract 7: Assessment of Clavien-Dindo Classification in patients with Metastatic Clear Cell Renal Cell Carcinoma (mccRCC) who received Perioperative Cabozantinib and Nivolumab on Cyto-KIK Clinical Trial9:32 AM- 9:39 AMKarie Runcie, MD
New York Presbyterian Hosital, Columbia University
Abstract 8: Genetic Ancestry and Molecular Correlations in Patients with Kidney Cancers9:40 AM- 9:47 AMRitesh Kotecha, MD
Memorial Sloan Kettering Cancer Center
Panel Discussion and Question and Answer9:48 AM- 10:00 AM
Break10:00 AM- 10:15 AM
Session 10: Genetics in Kidney Cancer Demonstrated Through Case-Based Presentations
Zilker 3-4
10:15 AM- 11:45 AMMaria Carlo, MD
Memorial Sloan Kettering Cancer Center
Who, What, When, Where, and Why of Genetics in Kidney Cancer: Considerations for the Genetics Consensus Statement10:15 AM- 10:35 AMMaria Carlo, MD
Memorial Sloan Kettering Cancer Center
Somatic Testing Considerations10:35 AM- 10:55 AMElizabeth “Lisa” Henske, MD
Brigham and Women’s Hospital
Genetic of Kidney Cancer: Systemic Therapy for VHL and HLRCC-Associated Cancers10:55 AM- 11:15 AMRamprasad “Ram” Srinivasan, MD, PhD
National Cancer Institute at the National Institutes of Health
Abstract 4: Delineating Clinical and Radiologic Features of Rare Kidney Cancer Genetic Syndromes11:15 AM- 11:22 AMPamela I. Causa Andrieu, MD
Memorial Sloan Kettering Cancer Center
Panel Discussion and Question and Answer11:23 AM- 11:45 AM
Session 11: Risk Stratification: The Evolving State of RCC
Zilker 3-4
11:45 AM- 12:30 PMKaty Beckermann, MD, PhD
Vanderbilt University Medical Center
Using Proper Risk Stratification and How to do it Accurately11:45 AM- 12:00 PMDaniel Heng, MD, MPH, FRCPC
Tom Baker Cancer Centre
What’s Wrong with the Guidelines and How Do We Move Forward?12:00 PM- 12:15 PMA. Ari Hakimi, MD
Memorial Sloan Kettering Cancer Center
Panel Discussion and Question and Answer12:15 PM- 12:30 PM
Break and Lunch Available
Zilker North Lobby and Zilker 1-2
12:30 PM- 1:30 PM
Session 12: Kidney Cancer Association Awards Recognition Ceremony
Zilker 3-4
12:45 PM- 1:25 PMBradley C. Leibovich, MD
Mayo Clinic

Brian Rini, MD
Vanderbilt-Ingram Cancer Center
Presentation of the Eugene P. Schonfeld Award 12:45 PM- 12:55 PMDavid F. McDermott, MD
Beth Israel Deaconess
Presentation of the Christopher G. Wood Rising Star Award12:55 PM- 1:05 PMDaniel Shapiro, MD
University of Wisconsin-Madison
Presentation of the Kidney Cancer Association Nicholas J. Vogelzang Humanitarian Award1:05 PM- 1:25 PMDianne Vogelzang on behalf of
Nicholas J. Vogelzang, MD, FASCO, FACP
Comprehensive Cancer Centers of Nevada
Session 13: WoodFire®
WoodFire® is an exciting chance to watch clinicians debate the various treatment options for each presented oncology case. It’s the fiercest tumor board you’ll ever see!
Zilker 3-4
1:25 PM- 2:25 PM
Case Presentation and Discussion 11:25 PM- 1:40 PMDaniel Shapiro, MD
University of Wisconsin-Madison
Case Presentation and Discussion 21:40 PM- 1:55 PMVignesh Packiam, MD
University of Iowa
Case Presentation and Discussion 31:55 PM- 2:10 PMWalter Stadler, MD
University of Chicago Comprehensive Cancer Center
Case Presentation and Discussion 42:10 PM- 2:25 PMRana McKay, MD
University of California, San Diego
Meeting Adjourn
Zilker 3-4
2:25 PM- 2:40 PMEric A. Singer, MD, MA, MS, FACS, FASCO
Ohio State Wexner Medical Center